Freelance Medical Writer & Consultant | Accurate, evidence-based, and timely medical content for laboratories, healthcare payors, managed healthcare companies, biotech companies, and other clients
📱💊 I came across an article evaluating digital health products for coverage & reimbursement. It was really interesting. First, full disclosure…I have evaluated and worked on digital therapeutics (DTx) projects, but this article does not include any DTx that I have worked with in the past. The rapid growth of digital health tools, including apps, wearables, and DTx, is transforming healthcare. But how do payers decide which of these products to cover? 🤔 This recent study evaluated the rationale of payers in determining which digital health products should be covered. 🔍 Key Findings - Products with FDA approval, prescription status, and potential to treat conditions are prioritized for evaluation. - Payers are more likely to review products that can improve population health metrics and reduce healthcare costs. (Not surprising…) - Efficient differentiation of digital health products is crucial to avoid overwhelming healthcare systems. (Very important!) 📊 Why It Matters As digital health continues to expand, understanding which products to evaluate for coverage can streamline healthcare delivery and enhance patient outcomes. Payers need criteria to make informed decisions that benefit both providers and patients. 💡 What criteria do you think should be included? Are they missing anything? You can read the full article at https://buff.ly/3YKeVmP
